Relevance (Person of Interest)

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Retrieved on: 
Monday, August 15, 2022
Cyprus Securities and Exchange Commission, VRNA, Telephone, Madison Avenue, Jefferies Group, Exercise, European Union (Withdrawal) Act 2018, United Kingdom, GLOBE, Form, ADS, SEC, Investment, Qualifying investor alternative investment fund, Prospectus, Sale, American depositary receipt, LLC, Order, Form S-3, European Economic Area, Nicollet Mall, Financial services, Urban economics, Company, Person, Attention, Relevance (Person of Interest), Finance, U.S. Securities and Exchange Commission, Nasdaq, Regulation, Time, Financial Services and Markets Act 2000, Degenerative disease, Security (finance), EU

The aggregate gross proceeds from the offering were approximately $150 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Verona Pharma.

Key Points: 
  • The aggregate gross proceeds from the offering were approximately $150 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Verona Pharma.
  • All ADSs in the offering were offered by Verona Pharma.
  • Jefferies, Piper Sandler & Co. and Truist Securities acted as the book-running managers for the offering.
  • BTIG, H.C. Wainwright & Co. and Wedbush PacGrow acted as co-managers for the offering.

DGAP-News: Eleving Group S.A.: Unaudited 6M 2022 results on 15 August 2022 - Invitation to earnings call on 17 August 2022

Retrieved on: 
Thursday, August 11, 2022
Securities Act of 1933, Comment, United Kingdom, KID, Sale, Prospectus, Group, DGAP, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, European Economic Area, Communication, Financial services, Urban economics, Relevance (Person of Interest), Person, The Elevation Group, News, Finance, MIFID, Financial Times, Financial Services and Markets Act 2000, Security (finance), Property management, Baltic states

Eleving Group and its group companies (the "Group"), specializing in vehicle and consumer financing, cordially invite investors and analysts to an earnings call with the Management Board on 17 August 2022, 15:00 CET, following the publication of its unaudited 6M 2022 results on 15 August 2022.

Key Points: 
  • Eleving Group and its group companies (the "Group"), specializing in vehicle and consumer financing, cordially invite investors and analysts to an earnings call with the Management Board on 17 August 2022, 15:00 CET, following the publication of its unaudited 6M 2022 results on 15 August 2022.
  • Group CEO Modestas Sudnius and CFO Maris Kreics will present and comment on the unaudited results by means of a presentation.
  • The presentation for the earnings call will be available here as of 16 August2022.
  • Eleving Group comprises a number of financial technology companies with a global presence.

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

Retrieved on: 
Thursday, August 11, 2022
U.S. Securities and Exchange Commission, VRNA, Telephone, Madison Avenue, Jefferies Group, European Union (Withdrawal) Act 2018, Truist Financial, United Kingdom, GLOBE, Form, ADS, SEC, Investment, Qualifying investor alternative investment fund, Prospectus, Sale, American depositary receipt, LLC, Order, Form S-3, European Economic Area, Nicollet Mall, Financial services, Urban economics, Company, Person, Attention, Relevance (Person of Interest), Finance, Offering, Nasdaq, Regulation, Time, Financial Services and Markets Act 2000, Degenerative disease, Security (finance), EU

LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its upsized public offering of 12,400,000 American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share, at a price of $10.50 per ADS, for aggregate gross proceeds of $130.2 million before deducting underwriting discounts and commissions (the Offering).

Key Points: 
  • LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its upsized public offering of 12,400,000 American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share, at a price of $10.50 per ADS, for aggregate gross proceeds of $130.2 million before deducting underwriting discounts and commissions (the Offering).
  • All ADSs in the Offering are being offered by Verona Pharma.
  • In addition, Verona Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,860,000 ADSs at the public offering price, less the underwriting discount and commission.
  • The Offering is expected to close on August 15, 2022, subject to the satisfaction of customary closing conditions.

Verona Pharma plc Announces Proposed Underwritten Public Offering

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, VRNA, Telephone, Madison Avenue, Jefferies Group, European Union (Withdrawal) Act 2018, Truist Financial, ADSS, United Kingdom, GLOBE, Form, SEC, Investment, Qualifying investor alternative investment fund, Prospectus, Sale, American depositary receipt, LLC, Order, European Economic Area, Form S-3, Nicollet Mall, Financial services, Urban economics, Company, Person, Attention, Relevance (Person of Interest), Finance, Offering, Nasdaq, Regulation, Time, Financial Services and Markets Act 2000, Degenerative disease, Security (finance), EU

LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share (the Offering).

Key Points: 
  • LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share (the Offering).
  • All ADSs in the Offering will be offered by Verona Pharma.
  • The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.
  • In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.

DGAP-News: SFC Energy AG: Capital increase successfully placed

Retrieved on: 
Thursday, July 28, 2022
European Union (Withdrawal) Act 2018, Directive 2014/65/EU, Sale, Investment, Urban economics, United Kingdom, Relevance (Person of Interest), Judgement of the German Federal Court of Justice on Google's autocomplete function, Forward-looking statement, Person, Article 19, European Economic Area, US, Nature, Prospectus, News, Finance, Manufacturing, Company, Security (finance), Terminology, Communication, Order, II, DGAP, Physikalisch-Technische Bundesanstalt, Financial Services and Markets Act 2000, Financial services, Medical device, EU

The public offering in Germany will be made solely by means of, and on the basis of, a published securities prospectus.

Key Points: 
  • The public offering in Germany will be made solely by means of, and on the basis of, a published securities prospectus.
  • This announcement is not an offer of securities for sale in the United States.
  • Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.
  • All information presented or contained in this press release is subject to verification, correction, completion and change without notice.

DGAP-News: TAG Immobilien AG announces successful completion of capital increase

Retrieved on: 
Tuesday, July 26, 2022
European Union (Withdrawal) Act 2018, Sale, Acquisition, Knowledge, Investment, United Kingdom, Council, U.S. Securities and Exchange Commission, Federal Financial Supervisory Authority, Judgement of the German Federal Court of Justice on Google's autocomplete function, Forward-looking statement, European, Relevance (Person of Interest), Person, Securities Act of 1933, European Economic Area, Prospectus, News, Article, Offering, Finance, Review, Company, European Parliament, Joint Global Change Research Institute, Communication, DGAP, Contract, Financial Services and Markets Act 2000, Physikalisch-Technische Bundesanstalt, Financial services, Security (finance), EU, Regulation

This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.

Key Points: 
  • This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.
  • An investment decision regarding the securities of the Company should only be made on the basis of such securities prospectus.
  • The securities prospectus is available free of charge on the website of the Company (www.tag-ag.com/investor-relations) under the "Investor Relations Capital Increase 2022" section.
  • 26.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

DGAP-News: TAG Immobilien AG announces results of subscription offer

Retrieved on: 
Tuesday, July 26, 2022
European Union (Withdrawal) Act 2018, Sale, Acquisition, Knowledge, Investment, United Kingdom, Council, U.S. Securities and Exchange Commission, Federal Financial Supervisory Authority, Judgement of the German Federal Court of Justice on Google's autocomplete function, Forward-looking statement, European, Relevance (Person of Interest), Person, Securities Act of 1933, European Economic Area, Prospectus, News, Article, Offering, Finance, Review, Company, European Parliament, Joint Global Change Research Institute, Communication, DGAP, Contract, Financial Services and Markets Act 2000, Physikalisch-Technische Bundesanstalt, Financial services, Security (finance), EU, Regulation

This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.

Key Points: 
  • This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.
  • An investment decision regarding the securities of the Company should only be made on the basis of such securities prospectus.
  • This release is not an offer of securities for sale in the United States.
  • 26.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

Securitas has completed the acquisition of Stanley Security

Retrieved on: 
Friday, July 22, 2022
Group, Acquisition, Time, United Kingdom, Securitas AB, Stanley Black & Decker, CEO, Relevance (Person of Interest), Person, Solution, Compliance, Securities Act of 1933, Financial services, Risk management, Income, Safety, SEK, Prospectus, Finance, Electronic, Review, Company, Security (finance), MUSD, Guard, Growth, CEST, Financial Services and Markets Act 2000, Order, Cryptocurrency, EEA, Securitas

STOCKHOLM, July 22, 2022 /PRNewswire/ --The acquisition of Stanley Security is now completed and is consolidated into Securitas as of July 22, 2022.

Key Points: 
  • STOCKHOLM, July 22, 2022 /PRNewswire/ --The acquisition of Stanley Security is now completed and is consolidated into Securitas as of July 22, 2022.
  • On December 8, 2021, Securitas announced it had signed an agreement to acquire the Electronic Security Solutions business from Stanley Black & Decker Inc. ("Stanley Security") for a purchase price of MUSD 3200 on a debt and cash free basis.
  • "This transformational acquisition makes us a strong provider of tech-enabled security solutions and a leading partner to our clients on a global scale.
  • We are extremely pleased that the acquisition now is formally completed, and I want to welcome all of Stanley Security's clients and employees into the Securitas Group," says Magnus Ahlqvist, President and CEO of Securitas.

Securitas has completed the acquisition of Stanley Security

Retrieved on: 
Friday, July 22, 2022
Group, Acquisition, Time, United Kingdom, Securitas AB, Stanley Black & Decker, CEO, Relevance (Person of Interest), Person, Solution, Compliance, Securities Act of 1933, Financial services, Risk management, Income, Safety, SEK, Prospectus, Finance, Electronic, Review, Company, Security (finance), MUSD, Guard, Growth, CEST, Financial Services and Markets Act 2000, Order, Cryptocurrency, EEA, Securitas

STOCKHOLM, July 22, 2022 /PRNewswire/ --The acquisition of Stanley Security is now completed and is consolidated into Securitas as of July 22, 2022.

Key Points: 
  • STOCKHOLM, July 22, 2022 /PRNewswire/ --The acquisition of Stanley Security is now completed and is consolidated into Securitas as of July 22, 2022.
  • On December 8, 2021, Securitas announced it had signed an agreement to acquire the Electronic Security Solutions business from Stanley Black & Decker Inc. ("Stanley Security") for a purchase price of MUSD 3200 on a debt and cash free basis.
  • "This transformational acquisition makes us a strong provider of tech-enabled security solutions and a leading partner to our clients on a global scale.
  • We are extremely pleased that the acquisition now is formally completed, and I want to welcome all of Stanley Security's clients and employees into the Securitas Group," says Magnus Ahlqvist, President and CEO of Securitas.

DGAP-News: TAG Immobilien AG resolves on €200m fully underwritten capital increase with subscription rights to refinance the bridge facility in relation to the acquisition of ROBYG S.A.

Retrieved on: 
Friday, July 8, 2022
Review, Joint Global Change Research Institute, Acquisition, European Parliament, European Economic Area, Securities Act of 1933, Offering, Article, Judgement of the German Federal Court of Justice on Google's autocomplete function, Physikalisch-Technische Bundesanstalt, Sale, Company, U.S. Securities and Exchange Commission, European Union (Withdrawal) Act 2018, Prospectus, Council, United Kingdom, Contract, Person, Investment, Urban economics, Communication, European, Financial Services and Markets Act 2000, Federal Financial Supervisory Authority, News, Relevance (Person of Interest), Financial services, Finance, DGAP, Knowledge, Forward-looking statement, Security (finance), EU, Regulation

This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.

Key Points: 
  • This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.
  • An investment decision regarding the securities of the Company should only be made on the basis of such securities prospectus.
  • This release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.
  • 08.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.